CAS 170787-99-2

Efaproxiral sodium

Description:

Efaproxiral sodium, also known as RSR13, is a synthetic compound primarily studied for its potential therapeutic applications, particularly in enhancing the efficacy of radiotherapy in cancer treatment. It functions as a hemoglobin modifier, aiming to improve oxygen delivery to hypoxic tumor regions, thereby increasing the sensitivity of tumors to radiation. The compound is characterized by its ability to bind to hemoglobin, altering its oxygen affinity and facilitating better oxygenation of tissues. Efaproxiral sodium is typically administered intravenously and has been evaluated in clinical trials for various malignancies. Its chemical structure includes a sodium salt form, which enhances its solubility in aqueous solutions, making it suitable for parenteral administration. While promising in preclinical and early clinical studies, the overall clinical utility and approval status of efaproxiral sodium have been subject to ongoing research and evaluation. As with many investigational drugs, its safety profile, efficacy, and potential side effects are critical areas of study in the context of cancer therapy.

Formula: C₂₀H₂₂NNaO₄

InChI: InChI=1/C20H23NO4.Na/c1-13-9-14(2)11-16(10-13)21-18(22)12-15-5-7-17(8-6-15)25-20(3,4)19(23)24;/h5-11H,12H2,1-4H3,(H,21,22)(H,23,24);/q;+1/p-1

SMILES: Cc1cc(C)cc(c1)N=C(Cc1ccc(cc1)OC(C)(C)C(=O)O)O.[Na]

Synonyms:

• Sodium 2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoate
• RSR-13
• Unii-3L83qp52xi
• Efaproxiral (sodiuM salt forM)
• Efaproxiral Sodium (RSR13)
• Rsr 13 sodium
• EFAPROXIRAL SODIUM
• 2-[4-[2-(3,5-Dimethylphenylamino)-2-oxoethyl]phenoxy]-2-methylpropionic acid
• 2-(4-(2-((3,5-Dimethylphenyl)amino)-2-oxoethyl)phenoxy)-2-methylpropanoic acid monosodium salt
• 2-[4-[2-[(3,5-Dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic Acid Sodium Salt
• Propanoic acid, 2-(4-(2-((3,5-dimethylphenyl)amino)-2-oxoethyl)phenoxy)-2-methyl-, monosodium salt

Efaproxiral Sodium

CAS: 170787-99-2

Formula: C₂₀H₂₂NNaO₄

Purity: >98.0%(T)(HPLC)

Color and Shape: White to Almost white powder to lump

Molecular weight: 363.39

Ref: 3B-E1356

Efaproxiral sodium

CAS: 170787-99-2

Formula: C₂₀H₂₂NNaO₄

Purity: 98%

Color and Shape: Solid

Molecular weight: 363.3828

Ref: IN-DA00ABNP

Efaproxiral Sodium

CAS: 170787-99-2

Efaproxiral Sodium

Purity: ≥95%

Molecular weight: 363.38g/mol

Ref: 54-BUP16671

Efaproxiral Sodium

CAS: 170787-99-2

Efaproxiral Sodium (RSR13 sodium), a synthetic allosteric modifier of hemoglobin, is utilized for brain metastases originating from breast cancer.

Formula: C₂₀H₂₃NO₄·Na

Purity: 97.92%

Color and Shape: Solid

Molecular weight: 363.38

Ref: TM-T6482

Sodium 2-(4-(2-((3,5-dimethylphenyl)amino)-2-oxoethyl)phenoxy)-2-methylpropanoate

CAS: 170787-99-2

Formula: C₂₀H₂₂NNaO₄

Purity: 99%

Molecular weight: 363.389

Ref: 10-F242253

Efaproxiral sodium

Controlled Product

CAS: 170787-99-2

Efaproxiral sodium is a radiation sensitizer that inhibits the production of maleate, an inhibitor of growth factor. It also has been shown to increase the proliferation of epidermal cells and stimulate the synthesis of EGF. Clinical studies have shown that efaproxiral sodium can be used as a radiosensitizer in patients with cancer. Efaproxiral sodium is structurally related to sildenafil, which is used for erectile dysfunction. Efaproxiral sodium also has been shown to inhibit tumor growth in cultures by inducing hypoxia-dependent apoptosis.

Formula: C₂₀H₂₂NNaO₄

Purity: Min. 95%

Molecular weight: 363.38 g/mol

Ref: 3D-FE150510